T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 4, 2012, Pages 1233-1238

  Gil Cruz, Cristina ^a   Perez Shibayama, Christian ^a,b   Firner, Sonja ^a   Waisman, Ari ^c   Bechmann, Ingo ^d   Thiel, Volker ^a   Cervantes Barragan, Luisa ^a   Ludewig, Burkhard ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Coronavirus; Encephalomyelitis; Neutralizing antibodies

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD BRAIN BARRIER; CELL INTERACTION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME ACTIVATION; HELPER CELL; HYPOTHALAMUS; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; VIRUS REPLICATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CYTIDINE DEAMINASE; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOGLOBULIN M; MICE; MICE, KNOCKOUT; MURINE HEPATITIS VIRUS; T-LYMPHOCYTES, HELPER-INDUCER;

CORONAVIRUS; MURINE HEPATITIS VIRUS; MUS;

EID: 84856371485     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115154109     Document Type: Article

References (35)

1. Bhat R, Steinman L (2009) Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64:123-132.
2. Hafler DA, et al.; International Multiple Sclerosis Genetics Consortium (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-862. (Pubitemid 47347319)
3. Baranzini SE, et al. (2010) Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464:1351-1356.
4. Pugliatti M, et al. (2006) Evidence of early childhood as the susceptibility period in multiple sclerosis: Space-time cluster analysis in a Sardinian population. Am J Epidemiol 164:326-333. (Pubitemid 44297340)
5. Münz C, Lünemann JD, Getts MT, Miller SD (2009) Antiviral immune responses: Triggers of or triggered by autoimmunity? Nat Rev Immunol 9:246-258.
6. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A (2010) Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 67:824-830.
7. Soldan SS, et al. (1997) Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 3:1394-1397. (Pubitemid 28011041)
8. Arbour N, Day R, Newcombe J, Talbot PJ (2000) Neuroinvasion by human respiratory coronaviruses. J Virol 74:8913-8921.
9. Boucher A, Desforges M, Duquette P, Talbot PJ (2007) Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin Immunol 123:258-267. (Pubitemid 46830769)
10. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6:667-679.
11. Prineas JW (1979) Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 203:1123-1125.
12. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple sclerosis. Lancet Neurol 7:852-858.
13. Sola P, et al. (2011) Primary progressive versus relapsing-onset multiple sclerosis: Presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 17: 303-311.
14. Stauch C, et al. (2011) Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: Quantitative versus qualitative IgM analysis. Mult Scler 17:327-334.
15. Pohl D, et al. (2010) Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol 257: 212-216.
16. Jacobi C, Lange P, Reiber H (2007) Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: Discrimination between microorganism-driven and polyspecific immune response. J Neuroimmunol 187:139-146. (Pubitemid 47001538)
17. Matthews AE, et al. (2001) Antibody is required for clearance of infectious murine hepatitis virus A59 from the central nervous system, but not the liver. J Immunol 167: 5254-5263. (Pubitemid 33009763)
18. Ramakrishna C, Stohlman SA, Atkinson RD, Shlomchik MJ, Bergmann CC (2002) Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells. J Immunol 168:1204-1211. (Pubitemid 34094486)
19. Ramakrishna C, Bergmann CC, Atkinson R, Stohlman SA (2003) Control of central nervous system viral persistence by neutralizing antibody. J Virol 77:4670-4678. (Pubitemid 36402816)
20. Marques CP, et al. (2011) CXCR3-dependent plasma blast migration to the central nervous system during viral encephalomyelitis. J Virol 85:6136-6147.
21. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: The two extremes of a wide spectrum. Nat Rev Immunol 6:231-243. (Pubitemid 43290992)
22. Harada Y, Muramatsu M, Shibata T, Honjo T, Kuroda K (2003) Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med 197: 1779-1785. (Pubitemid 36745352)
23. Diamond MS, et al. (2003) A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 198:1853-1862. (Pubitemid 38032118)
24. Züst R, et al. (2007) Identification of coronavirus non-structural protein 1 as a major pathogenicity factor - implications for the rational design of live attenuated coronavirus vaccines. PLoS Pathog 3:e109.
25. Bergmann CC, Lane TE, Stohlman SA (2006) Coronavirus infection of the central nervous system: Host-virus stand-off. Nat Rev Microbiol 4:121-132. (Pubitemid 43158155)
26. Waisman A, Croxford AL, Demircik F (2008) New tools to study the role of B cells in cytomegalovirus infections. Med Microbiol Immunol (Berl) 197:145-149.
27. Cervantes-Barragán L, et al. (2009) Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol 182: 1099-1106.
28. Oxenius A, et al. (1996) CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med 183:2209-2218. (Pubitemid 26158912)
29. Kumar V, et al. (2010) Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathway. Blood 115:4725-4733.
30. Phares TW, Marques CP, Stohlman SA, Hinton DR, Bergmann CC (2011) Factors supporting intrathecal humoral responses following viral encephalomyelitis. J Virol 85: 2589-2598.
31. Dandekar AA, Jacobsen G, Waldschmidt TJ, Perlman S (2003) Antibody-mediated protection against cytotoxic T-cell escape in coronavirus-induced demyelination. J Virol 77:11867-11874. (Pubitemid 37339840)
32. Racine R, et al. (2011) IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J Immunol 186:1011-1021.
33. Bosch X, Saiz A, Ramos-Casals M BIOGEAS Study Group (2011) Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 7:165-172.
34. Ludewig B, et al. (2000) Induction of optimal anti-viral neutralizing B cell responses by dendritic cells requires transport and release of virus particles in secondary lymphoid organs. Eur J Immunol 30:185-196. (Pubitemid 30011779)
35. Cervantes-Barragan L, et al. (2009) TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens. Eur J Immunol 39:126-135.